Home
About
Overview
Sharing Data
ORCID
Help
History (64)
Distinct CpG oligonucleotide sequences activate human gamma delta T cells via interferon-alpha/-beta.
PU.1 is essential for CD11c expression in CD8(+)/CD8(-) lymphoid and monocyte-derived dendritic cells during GM-CSF or FLT3L-induced differentiation.
Structure of the monophosphoryl lipid A moiety obtained from the lipopolysaccharide of Chlamydia trachomatis.
The CD11/CD18 integrins: characterization of three novel LPS signaling receptors.
Disease-modifying therapies in Alzheimer's disease: how far have we come?
See All 64 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Disease-modifying therapies in Alzheimer's disease: how far have we come?
H?ll M, Berger M, Heneka M. Disease-modifying therapies in Alzheimer's disease: how far have we come? Drugs. 2006; 66(16):2075-93.
View in:
PubMed
subject areas
Alzheimer Disease
Amyloid
Amyloid beta-Peptides
Amyloid beta-Protein Precursor
Amyloid Precursor Protein Secretases
Animals
Anti-Inflammatory Agents, Non-Steroidal
Antioxidants
Cholinesterase Inhibitors
Clinical Trials as Topic
Enzyme Activation
Estrogens
Excitatory Amino Acid Antagonists
Gonadotropin-Releasing Hormone
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Immunotherapy
Memantine
Metalloendopeptidases
Monoamine Oxidase Inhibitors
Nerve Growth Factors
Pharmacoepidemiology
PPAR gamma
tau Proteins
authors with profiles
Michael Thomas Heneka MD